CREB1 Double Nickase Plasmid (h): sc-400160-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CREB1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CREB1 Double Nickase Plasmid (h) and CREB1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CREB1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CREB1 Antibody (X-12): sc-240
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CREB1 Double Nickase Plasmid (h) | sc-400160-NIC | 20 µg | $410.00 | |||
CREB1 Double Nickase Plasmid (h2) | sc-400160-NIC-2 | 20 µg | $410.00 |
CREB1 encodes the cAMP response element-binding protein 1 (CREB1), a bZIP transcription factor that binds CRE motifs to coordinate stimulus-dependent gene expression. CREB1 integrates signaling from cAMP/PKA, Ca2+/calmodulin kinases, and MAPK/ERK pathways, shaping programs involved in neuronal plasticity, metabolism, cell-cycle control, and stress responses. Through phosphorylation-dependent coactivator recruitment (e.g., CBP/p300), CREB1 modulates chromatin and transcriptional outputs across diverse cell types. Dysregulated CREB1 activity has been associated with altered immune and inflammatory signaling, neuropsychiatric phenotypes, and oncogenic transcriptional networks, making it a widely used node for pathway and disease-mechanism studies.
CREB1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CREB1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CREB1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CREB1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CREB1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.